Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients

This is a guideline for pediatric patients age 1 month to 18 years who are receiving antineoplastic medication and who are at risk of experiencing antineoplastic-induced nausea and vomiting (AINV). The guideline examines methods for the prevention and optimal control of acute AINV. Recommendations for pharmacological interventions are provided based on emetic risk, and the use of adjunctive, non-pharmacological interventions is discussed. Primary outcomes of interest are therapeutic efficacy and safety.